Until now, 2 types of immune checkpoint inhibitors have shown clinical effectivity against a broad range of tumours: anti-CTLA-4 inhibitors (e.g. ipilimumab and tremelimumab) and PD-(L)1 inhibitors (e.g. nivolumab, pembrolizumab, atezolizumab, avelumab). There is a rationale to combine these types of immune checkpoint inhibitors because anti-CTLA-4 inhibitors increase the expression of PD-L1 in some tumours and the combination of anti-CTLA-4 inhibition and PD-(L)1 inhibition favours effector T cell recruitment in preclinical tumour models [1]. In addition, several clinical trials have shown that combining an anti-CTLA-4 inhibitor and an anti-PD-(L)1 inhibitor increases the overall response compared with an anti-PD-(L)1 inhibitor alone [2]. However, the combination also induces more serious adverse events (grade ≥3).
Both MGD019 and AK104 are bispecific, tetravalent antibodies targeting both CTLA-4 and PD-1. This makes these molecules potential new candidates to simultaneously block CTLA-4 and PD-L1, hence mimicking the clinical effect of a dual immune checkpoint blockade with e.g. nivolumab plus ipilimumab. In a phase 1, first-in-human, open-label, dose-escalation study, 33 patients with advanced solid tumours were treated with MGD019 in dose escalation from 0.03 to 10 mg/kg [3].
Treatment-related adverse events occurred in 26 of 33 (78.8%) patients, most commonly fatigue (24%), nausea, arthralgia, pruritus, and rash (18% each). The rate of grade ≥3 treatment-related adverse events was 24.2%. Among 25 response-evaluable patients, 4 objective responses were observed also in tumour types that are typically not responsive to checkpoint blockade; 9 patients had stable disease. A phase 2 monotherapy in select expansion cohorts is forthcoming.
In addition, a clinical phase 1 trial with AK104 in 18 patients with mesothelioma, showed 3 out of 18 patients (16.7%) with a grade 3/4 treatment-related adverse event and another 9 subjects experienced grade 1/2 treatment-related adverse events [4]. Confirmed objective response rate was 20%, with a disease control rate of 80%. Median progression-free survival (PFS) was 5.6 months; median PFS in patients who received AK104 in a dose of 4 mg/kg or more (n=16) was 12.9 months.
- Shi LZ, et al. Nat Commun. 2016; 7:12335.
- Yang Y, e al. Front Pharmacol. 2020; 11: 40.
- Sharma M, et al. A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours. ESMO 2020 Virtual Meeting, abstract 1020O.
- Millward M, et al. Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies. ESMO 2020 Virtual Meeting, abstract 1021O.
Posted on
Previous Article
« PD-(L)1, LAG-3, and TIM blockade Next Article
Palbociclib effective in ER-positive endometrial cancer »
« PD-(L)1, LAG-3, and TIM blockade Next Article
Palbociclib effective in ER-positive endometrial cancer »
Table of Contents: ESMO 2020
Featured articles
COVID-19 and Cancer
Breast Cancer
Gastrointestinal Cancers
Lung Cancer
Melanoma
Genitourinary Cancers
Bladder cancer risk and early detection
Gynaecological Cancers
Basic Science
Related Articles
November 25, 2020
Adjuvant immune checkpoint inhibition after complete resection
November 25, 2020
Immuno-combination therapy in metastatic melanoma
November 25, 2020
Neoadjuvant treatment in patients with high-risk early breast cancer
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy